[Skip to Navigation]
Sign In
Special Communication
January 20, 2022

Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease

Author Affiliations
  • 1Department of Dermatology, Stanford University School of Medicine, Redwood City, California
  • 2Dermatology Service, South Texas Veterans Health Care System, San Antonio
  • 3Florida Dermatology and Skin Cancer Centers, Lake Wales
  • 4Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut
  • 5Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 6Division of Dermatology, University of Kansas, Kansas City
  • 7Department of Pathology (Dermatopathology), The University of Texas MD Anderson Cancer Center, Houston
  • 8Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
  • 9Section of Dermatology, University of Chicago, Chicago, Illinois
  • 10University Hospitals Cleveland Medical Center, Department of Dermatology, Case Western Reserve University, Cleveland, Ohio
  • 11Division of Dermatology, Pennsylvania State College of Medicine, Hershey
  • 12Division of Oncology, Department of Medicine, Northwestern University Medical Center, Chicago, Illinois
  • 13Department of Surgery, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts
  • 14Department of Dermatology, Yonsei University College of Medicine, Seoul, South Korea
  • 15Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota
  • 16Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Women’s Cancer Center, Cancer Institute, Stanford University School of Medicine, Stanford, California
  • 17Department of Dermatology, University of California Davis, Sacramento
  • 18Department of Dermatology, University of Tsukuba, Tsukuba, Japan
  • 19Department of Dermatology, University of Missouri School of Medicine, Columbia
  • 20Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota
  • 21Department of Gynecologic Oncology, Metaxa Cancer Hospital, Piraeus, Greece
  • 22Department of Dermatology, University of California San Diego, San Diego
  • 23Department of Dermatology, Ed. Herriot Hospital Group (Pav. R), Lyon, France
  • 24Department of Pathology, University of Massachusetts Medical School–Baystate, Baystate Health, Springfield
  • 25Division of Plastic and Reconstructive Surgery, Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 26Division of Hematology, Oncology and Cell Therapy, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois
  • 27Division of Dermatology, Cooper Hospital, Rowan University, Camden, New Jersey
  • 28Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
  • 29Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York
  • 30Department of Gynaecology, University College, London, United Kingdom
  • 31Department of Dermatology, University of Minnesota, Minneapolis
  • 32Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 33Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York
  • 34Department of Dermatology, Henry Ford Hospital, Detroit, Michigan
  • 35Division of Surgery, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston
  • 36Department of Pathology, Upstate Medical University, Syracuse, New York
  • 37Department of Urology, Upstate Medical University, Syracuse, New York
  • 38Department of Radiology, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia
  • 39Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, Australia
  • 40Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston
  • 41Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Crete, Greece
  • 42Spokane Urology, Spokane, Washington
  • 43Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 44Division of Cancer Medicine, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston
  • 45Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada
  • 46Electrical Engineering, Kanagawa University, Kanagawa-ku, Yokohama, Japan
  • 47Cushing/Whitney Medical Library, Yale School of Medicine, Yale University, New Haven, Connecticut
  • 48Department of Otolaryngology–Head and Neck Surgery and Surgery (Organ Transplantation), Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 49Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 50Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
JAMA Oncol. 2022;8(4):618-628. doi:10.1001/jamaoncol.2021.7148
Abstract

Importance  Extramammary Paget disease (EMPD) is a frequently recurring malignant neoplasm with metastatic potential that presents in older adults on the genital, perianal, and axillary skin. Extramammary Paget disease can precede or occur along with internal malignant neoplasms.

Objective  To develop recommendations for the care of adults with EMPD.

Evidence Review  A systematic review of the literature on EMPD from January 1990 to September 18, 2019, was conducted using MEDLINE, Embase, Web of Science Core Collection, and Cochrane Libraries. Analysis included 483 studies. A multidisciplinary expert panel evaluation of the findings led to the development of clinical care recommendations for EMPD.

Findings  The key findings were as follows: (1) Multiple skin biopsies, including those of any nodular areas, are critical for diagnosis. (2) Malignant neoplasm screening appropriate for age and anatomical site should be performed at baseline to distinguish between primary and secondary EMPD. (3) Routine use of sentinel lymph node biopsy or lymph node dissection is not recommended. (4) For intraepidermal EMPD, surgical and nonsurgical treatments may be used depending on patient and tumor characteristics, although cure rates may be superior with surgical approaches. For invasive EMPD, surgical resection with curative intent is preferred. (5) Patients with unresectable intraepidermal EMPD or patients who are medically unable to undergo surgery may receive nonsurgical treatments, including radiotherapy, imiquimod, photodynamic therapy, carbon dioxide laser therapy, or other modalities. (6) Distant metastatic disease may be treated with chemotherapy or individualized targeted approaches. (7) Close follow-up to monitor for recurrence is recommended for at least the first 5 years.

Conclusions and Relevance  Clinical practice guidelines for EMPD provide guidance regarding recommended diagnostic approaches, differentiation between invasive and noninvasive disease, and use of surgical vs nonsurgical treatments. Prospective registries may further improve our understanding of the natural history of the disease in primary vs secondary EMPD, clarify features of high-risk tumors, and identify superior management approaches.

Add or change institution
1 Comment for this article
EXPAND ALL
Targeted agents for HER2 positive extramammary Paget disease: a safe and effective approach but more evidence is needed.
Michele Bartoletti, MD | Department of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
We have read with interest the systematic review article entitled “Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease” by Nour Kibbi et al., recently published in JAMA Oncology (1).

We want to congratulate the Authors for this comprehensive review article on a neglected disease, and make some contributions.

When invasive extramammary Paget disease (EMPD) metastasizes to distant sites as well as in case of wide locoregional disease that precludes local therapies (i.e., Imiquimod), no standard systemic treatments are available and responses to common chemotherapeutic agents are anecdotical. This aspect should be emphasized in the light of the relatively
high rate of HER2 overexpression seen in invasive EMPD where one out of four patients may have a HER2 amplified disease2.
In fact, HER2 amplification is not only a biomarker of biological aggressiveness in EMPD (3,4), but it also represents an actionable therapeutic target for anti-HER2 agents.

We have previously reported a case series of four patients with invasive EMPD of the vulva treated with the anti-HER2 monoclonal antibody trastuzumab plus weekly paclitaxel demonstrating that this approach is safe and effective in metastatic or locally advanced HER2 positive EMPD (4). In addition, the first patient described has responded to a second-line therapy with the antibody-drug conjugate trastuzumab-emtansine at disease progression to a trastuzumab-taxane therapy, proving that second generation anti-HER2 agents can overcome resistance to trastuzumab, as demonstrated in breast cancer.

After the publication, several women affected by this rare cancer have been referred to our center and among these, three have received trastuzumab and weekly paclitaxel with clinical benefit and partial responses at imaging. In our opinion, the value of HER2 testing in the diagnostic work up of EMPD is twice. First, it can influence the surgical approach in early disease (HER2 positive EMPD has a higher risk of lymph node involvement(3)) and, secondly, it can open to anti-HER2 target therapies for metastatic, recurrent or locoregional disease.

In conclusion, it is out of doubts that more solid evidence is needed to formally support changes in clinical practice in the management of HER2 positive EMPD, and researchers from different cooperative groups should work together with Companies in this effort. This comment is also a call for collaboration between groups in sharing experience about the management of EMPD.

Michele Bartoletti, Francesco Sopracordevole and Fabio Puglisi.


References:

1. Kibbi N, Owen JL, Worley B, et al. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncology. Published online January 20, 2022. doi:10.1001/jamaoncol.2021.7148
2. Richter CE, Hui P, Buza N, et al. HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. Journal of Clinical Pathology. 2010;63(6):544-547. doi:10.1136/jcp.2010.077446
3. Masuguchi S, Jinnin M, Fukushima S, et al. The expression of HER-2 in extramammary Paget’s disease. BioScience Trends.:5.
4. Bartoletti M, Mazzeo R, De Scordilli M, et al. Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget’s disease of the vulva. Int J Gynecol Cancer. 2020;30(11):1672-1677. doi:10.1136/ijgc-2020-001771
CONFLICT OF INTEREST: None Reported
READ MORE
×